Results 121 to 130 of about 2,307,809 (352)

Building Information Modelling: Challenges and Barriers in Implement of BIM for Interior Design Industry in Malaysia [PDF]

, 2018
A B Abd Hamid, Mohd Zafrullah Mohd Taib, A H N Abdul Razak, Mohamed Rashid Embi   +3 more
openalex   +1 more source

Return on sales in the Czech building industry? Does firm size matter? [PDF]

, 2023
Tomáš Krulický, Dominik Potužník
openalex   +1 more source

Priming the Pump: The Case for a Sector Based Approach to Impact Investing [PDF]

, 2012
The impact investing sector, while still in its infancy, has made remarkable progress in building awareness that business can generate a positive social impact.
Matt Bannick, Paula Goldman
core  

Developing evidence‐based, cost‐effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities

Molecular Oncology, EarlyView.
The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg, Joachim von Braun, Julio Celis, Anton Berns, Michael Baumann, Tit Albreht, Nancy Abou‐Zeid, Vanderlei Bagnato, Christian Brandts, Chien‐Jen Chen, Massimiliano di Pietro, Manjit Dosanjh, Thomas Dubois, Alexander Eggermont, Angelika Eggert, Ingemar Ernberg, Sara Faithfull, Johannes Förner, Stefan Fröhling, Manuel Heitor, Leroy Hood, Wei Jiang, Bengt Jönsson, Ravi Kannan, Maria Leptin, Su Li, Peter Lindgren, Douglas Lowy, Jun Ma, Alex Markham, Péter Nagy, Simon Oberst, M. Iqbal Parker, Danielle Rodin, Kevin Ryan, Joachim Schüz, Richard Sullivan, Josep Tabernero, Peter Turkson, Oliver Várhelyi, Harold Varmus, Chijie Wang, Elisabete Weiderpass, Nils Wilking   +43 more
wiley   +1 more source

Building a Material Research Ecosystem Between Industries and Universities in South Korea (Adv. Mater. 43/2023) [PDF]

, 2023
Ki Tae Nam, Hyuck Choo, Deok-Sin Kil, Chul‐Hong Kim, Cheolmin Park, Woon‐Ryeol Yu   +5 more
openalex   +1 more source

Cell surface interactome analysis identifies TSPAN4 as a negative regulator of PD‐L1 in melanoma

Molecular Oncology, EarlyView.
Using cell surface proximity biotinylation, we identified tetraspanin TSPAN4 within the PD‐L1 interactome of melanoma cells. TSPAN4 negatively regulates PD‐L1 expression and lateral mobility by limiting its interaction with CMTM6 and promoting PD‐L1 degradation.
Guus A. Franken, Andrea Abel Gutierrez, Imke van Rossum, Cornelia G. Spruijt, Michiel Vermeulen, Guido van Mierlo, Blanca Scheijen, Annemiek B. van Spriel   +7 more
wiley   +1 more source

A Novel Approach for Predicting CO₂ Emissions in the Building Industry Using a Hybrid Multi-Strategy Improved Particle Swarm Optimization–Long Short-Term Memory Model

Energies
The accurate prediction of carbon dioxide (CO2) emissions in the building industry can provide data support and theoretical insights for sustainable development.
Yuyi Hu, Bojun Wang, Yanping Yang, Liwei Yang   +3 more
doaj   +1 more source

International technology transfer: building theory from a multiple case-study in the aircraft industry [PDF]

, 2005
International technology transfer occurs frequently in international operations, for example in\ud cases of foreign direct investment where companies set-up existing manufacturing lines in new\ud locations.
Bruijn, Erik J. de, Steenhuis, Harm-Jan
core   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source